Efficacy of omalizumab in reducing latex allergy

Aruanno, Arianna; Chini, Raffaella; Nucera, Eleonora

doi:10.5114/ada.2021.110072

Cited by 3 publications

(4 citation statements)

References 9 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The authors demonstrated the efficacy of omalizumab in reducing skin and ocular symptoms in workers affected by latex allergy and exposed to a working environment with the presence of latex sources. In addition to this study, there are some case reports which have highlighted the benefits of this treatment in cases of contact urticaria or latex-induced asthma [ 113 , 114 ].…”

Section: Biological Drugsmentioning

confidence: 99%

Latex Allergy in Children

Arasi,

Barni,

Caminiti

et al. 2023

JCM

View full text Add to dashboard Cite

Notwithstanding the efforts made in the last decades to mitigate the consequences of natural rubber latex allergy, this disease continues to be a major health problem, especially in developing countries. The categories of patients with greater and frequent exposure to latex (such as health care professionals and, in the pediatric field, subjects who undergo repeated surgery, e.g., those suffering from spina bifida and urogenital malformations) have an increased risk of developing sensitization and allergy to latex. Herein we provide an overview of the current knowledge and practical recommendations with a focus on epidemiology, diagnostics, and management (including both prevention and therapy) in order to guide a correct recognition and containment of this potentially fatal condition.

show abstract

Section: Biological Drugsmentioning

confidence: 99%

Latex Allergy in Children

Arasi,

Barni,

Caminiti

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…Some studies have also been conducted investigating the efficacy of the anti-IgE monoclonal antibody omalizumab in the treatment of asthma and urticaria induced by latex [73]. In a 2004 randomized double-blind placebo-controlled study, Leynadier et al [74] demonstrated a significant reduction in conjunctival and cutaneous latex-allergy symptoms in nine patients after receiving one subcutaneous injection of omalizumab every 2 or 4 weeks for 16 weeks, and more recently Di Leo et al [75] and Aruanno et al [76 ▪▪ ] reported how patients with urticaria or asthma, during the omalizumab treatment, did not manifest clinical symptoms after any accidental contact with latex, thus showing how the use of omalizumab can also be extended as an adjunct to latex immunotherapy.…”

Section: Specific Immunotheraphy and Biological Drugsmentioning

confidence: 99%

Secondary prevention of latex allergy

Nettis

Casella

Incorvaia³

et al. 2022

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

Purpose of reviewThe present review addresses the secondary prevention in healthcare worker, healthcare setting, and in patients outside the healthcare setting. Recent findingsThere is sufficient knowledge of the broad aetiology of latex allergy for secondary preventive programmes to be widely adopted. Currently, avoidance of latex-containing surgical products is mandatory in the care of sensitized patients. They should also have a list of occult sources of natural rubber latex exposure and cross-reacting fruits. During all health-care procedures latex allergic patients should be treated in a 'latexfree' environment. Specific sublingual immunotherapy has been suggested as a suitable therapeutic option. It can be offered, in addition to symptomatic treatment, to selected patients, when avoidance measures are not feasible or effective. The use of omalizumab could also be extended as an adjunct to latex immunotherapy.

show abstract

“…36 puede neutralizar la IgE libre e inhibir la vía alérgica de la IgE. 38,39 El uso de omalizumab aún se encuentra en estudio; sin embargo, fue recién publicado, en 2019, el caso de una enfermera de 48 años que desde 2011 fue diagnosticada con urticaria por contacto al látex; le administraron antihistamínicos y glucocorticoides sin mejoría, por lo que fue tratada con 300 mg de omalizumab mostrando remisión total a las dos semanas. 40 Las indicaciones actuales para el tratamiento con este medicamento se limitan al asma alérgico persistente grave y la urticaria crónica espontánea, siempre que no se controle con el tratamiento convencional anti-H1 a la dosis máxima.…”

Section: Omalizumabunclassified

“…40 Las indicaciones actuales para el tratamiento con este medicamento se limitan al asma alérgico persistente grave y la urticaria crónica espontánea, siempre que no se controle con el tratamiento convencional anti-H1 a la dosis máxima. 39…”

Section: Omalizumabunclassified

Alergia al látex

Arce-Estrada,

Contreras-Verduzco

et al. 2022

Alergia, Asma E Inmunología Pediátricas

View full text Add to dashboard Cite

El látex es el material obtenido de la savia lechosa, sintetizada por células laticíferas especializadas y de la corteza dañada del árbol Hevea brasiliensis. Los alérgenos Hev b1, Hev b3, Hev b5 y Hev b6.02 son considerados alérgenos mayores y genuinos, indicadores clave en las pruebas diagnósticas. La alergia al látex es una reacción de hipersensibilidad inmediata causada por la exposición previa a productos que contienen las proteínas de látex y se desencadena en las personas con IgE específica para este material, donde también intervienen algunas células. El síndrome de látex-fruta es una asociación clínica entre la alergia al látex y la respuesta alérgica a ciertas frutas y/o verduras. La principal estrategia para el tratamiento es la evitación, el segundo escalón de tratamiento es el uso de antihistamínicos y esteroides para disminuir las manifestaciones clínicas.

show abstract

Efficacy of omalizumab in reducing latex allergy

Cited by 3 publications

References 9 publications

Latex Allergy in Children

Latex Allergy in Children

Secondary prevention of latex allergy

Alergia al látex

Contact Info

Product

Resources

About